The results of the study demonstrated that short-term oral treatment with ALA significantly increases peripheral insulin sensitivity in patients with type 2 diabetes mellitus, bringing it to a level almost similar to that of subjects in the control group. The gene discussed is INS; the disease is type 2 diabetes mellitus.